How well does lapatinib(Tykerb) work?

A summary of the drug's performance in clinical studies.

Clinical Benefits

The combination of TYKERB and capecitabine significantly extended the median time to progression (TTP) compared to capecitabine alone in HER2-positive metastatic breast cancer patients who had progressed after prior therapies. In another study for postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer, adding TYKERB to letrozole significantly improved progression-free survival (PFS) compared to letrozole alone.